Press Releases + New

Independent data safety monitoring board determines no safety issues in patients with NASH cirrhosis enrolled in NASH-CX trial

NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and cancer, announces the independent data safety monitoring board (DSMB) recently concluded that, from a safety perspective, the Company's NASH-CX trial sh...

The patent extends the Company's coverage to areas of future clinical investigation in diseases associated with elevations in iNOS

NORCROSS, Ga., June 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Galacto-Rhamnogalacturonate compositions for the treatment of a number of diseases associated with...

NORCROSS, Ga. , July 07, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold Shlevin , Ph.D., the Company's chief operating officer, will be presenting on behalf of the Company at the

Patent supports the Combination Immunotherapy trial utilizing GR-MD-02, now completed enrollment of second ascending dose cohort

80% of the patients enrolled have completed all 52 weeks of infusions and 99% of the doses have already been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial

NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to provide clarification of the press release issued August 14, 2017.  The following sentences in the

NORCROSS, Ga. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12

NORCROSS, Ga. , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics , Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received a Decision to Grant from the Chinese Patent Office for its patent application for